 Rigel Pharmaceuticals NASDAQ: RIGL stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration FDA for its leukemia treatment. Specifically, the FDA has approved REZLIDHIA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation. 